EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

This trial is testing different targeted therapy drugs (EGFR inhibitors) in people with non-small cell lung cancer (NSCLC) that has a specific genetic mutation in the EGFR gene, which makes tumors sensitive to these targeted drugs. The study includes patients at various stages, including those with spread to the brain. **You may be eligible if...** - You are 18 or older - You have NSCLC with a confirmed EGFR mutation (in tumor tissue or blood test) - Your cancer is stage III/IV or has come back and cannot be cured with radiation or surgery - You have not yet been treated with any EGFR-targeting therapy - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have already received an EGFR-targeted treatment - You have a serious medical condition that makes you unsuitable for the study medications - You are pregnant or breastfeeding - You are unwilling to use effective contraception Talk to your doctor to see if this trial is right for you.